文献速递乳腺癌消化系统肿瘤骨软组织肉瘤与黑色素瘤

ConquerFear心理干预降低癌症复发恐惧的随机试验

Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence.
PubMed 文献 · J Clin Oncol · 2017-11-02

本研究评估了基于理论与实证的心理社会干预(ConquerFear)对癌症复发恐惧(FCR)的影响。可治愈的乳腺癌、结直肠癌或黑色素瘤幸存者被随机分配接受五次面对面ConquerFear干预或注意力控制(放松疗法)。结果显示ConquerFear在治疗后即刻及3、6个月时显著降低FCRI总分,并在多个次要结局上改善。

要点

  • ConquerFear干预在治疗后即刻显著降低FCRI总分(P < .001)。
  • FCRI总分改善在3个月(P = .017)和6个月(P = .018)随访时仍维持。
  • 癌症特异性痛苦总分在3个月和6个月随访时仍显著改善。

核心结论

  • ConquerFear与注意力控制相比,在降低FCRI总分方面显示疗效,治疗后即刻及3、6个月均显著优于对照组。

研究设计与样本

  • 随机对照试验,纳入可治愈的乳腺癌、结直肠癌或黑色素瘤幸存者,完成治疗2个月至5年,年龄>18岁,筛查时FCRI严重度子量表评分高于临床 cutoff。
  • 222名参与者按1:1随机分配至ConquerFear组(121例)或注意力控制组(101例),ConquerFear为五次面对面 sessions,注意力控制为Taking-it-Easy放松疗法。
  • 主要结局为FCRI总分,在基线(T0)、治疗后即刻(T1)、3个月(T2)和6个月(T3)评估。

主要发现

  • ConquerFear组在T0至T1的FCRI总分(P < .001)和严重度子量表评分(P = .001)改善显著优于对照组,且在T2时维持(分别为P = .017和P = .023),FCRI总分在T3时仍维持(P = .018)。
  • T0至T1期间,ConquerFear组在三个FCRI子量表(应对、心理痛苦、触发因素)以及一般焦虑、癌症特异性痛苦(总分)、心理健康质量和元认知(总分)方面均有显著改善。
  • FCRI心理痛苦和癌症特异性痛苦(总分)的组间差异在T3时仍显著。

临床怎么用

  • 对于完成治愈性治疗的乳腺癌、结直肠癌或黑色素瘤幸存者,若FCRI严重度子量表评分高于临床 cutoff,可考虑提供ConquerFear干预以降低癌症复发恐惧。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Fear of cancer recurrence (FCR) is prevalent, distressing, and long lasting. This study evaluated the impact of a theoretically/empirically based intervention (ConquerFear) on FCR. Methods Eligible survivors had curable breast or colorectal cancer or melanoma, had completed treatment (not including endocrine therapy) 2 months to 5 years previously, were age > 18 years, and had scores above the clinical cutoff on the FCR Inventory (FCRI) severity subscale at screening. Participants were randomly assigned at a one-to-one ratio to either five face-to-face sessions of ConquerFear (attention training, metacognitions, acceptance/mindfulness, screening behavior, and values-based goal setting) or an attention control (Taking-it-Easy relaxation therapy). Participants completed questionnaires at baseline (T0), immediately post-therapy (T1), and 3 (T2) and 6 months (T3) later. The primary outcome was FCRI total score. Results Of 704 potentially eligible survivors from 17 sites and two online databases, 533 were contactable, of whom 222 (42%) consented; 121 were randomly assigned to intervention and 101 to control. Study arms were equivalent at baseline on all measured characteristics. ConquerFear participants had clinically and statistically greater improvements than control participants from T0 to T1 on FCRI total ( P < .001) and severity subscale scores ( P = .001), which were maintained at T2 ( P = .017 and P = .023, respectively) and, for FCRI total only, at T3 ( P = .018), and from T0 to T1 on three FCRI subscales (coping, psychological distress, and triggers) as well as in general anxiety, cancer-specific distress (total), and mental quality of life and metacognitions (total). Differences in FCRI psychological distress and cancer-specific distress (total) remained significantly different at T3. Conclusion This randomized trial demonstrated efficacy of ConquerFear compared with attention control (Taking-it-Easy) in reduction of FCRI total scores immediately post-therapy and 3 and 6 months later and in many secondary outcomes immediately post-therapy. Cancer-specific distress (total) remained more improved at 3- and 6-month follow-up.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Butow PN, Turner J, Gilchrist J, et al. Randomized Trial of ConquerFear: A Novel, Theoretically Based Psychosocial Intervention for Fear of Cancer Recurrence. J Clin Oncol. 2017. PMID: 29095681. doi:10.1200/JCO.2017.73.1257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。